Navigation Links
Ranbaxy Voluntarily Recalls Nitrofurantoin Capsules in the U.S.
Date:5/1/2009

PRINCETON, N.J., May 1 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI) announced today that it is conducting a voluntary recall of all lots of Nitrofurantoin (Monohydrate/Macrocrystals) Capsules, USP 100 mg currently on the market in the U.S.

Although certain lots of the product were determined to not be in conformity with the approved laboratory specifications, Ranbaxy decided to recall all the lots, as a matter of abundant caution, given its commitment to the health and safety of patients. Ranbaxy is continuing to look into the cause of such non-conformity.

The recall is being conducted in coordination with the FDA and will be a retail level recall. To the best of Ranbaxy's knowledge, the recalled product is unlikely to produce any serious adverse health effects. However, there is a remote possibility that the non-conforming product may increase the incidence of local non-serious gastrointestinal adverse events such as nausea and vomiting. All patients presently consuming and/or prescribed this formulation should consult their physicians for alternate and appropriate medication/treatment options.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.


'/>"/>
SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
2. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules
4. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
5. Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets
6. Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
7. Ranbaxy Launches Omeprazole 40 mg Capsules
8. ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets
9. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
10. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
11. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... largest privately-held contract pharmaceutical development and manufacturing organisation, today announced the ... company combining a leading CRO and the industry’s only Contract Commercial Organization ...
(Date:12/6/2016)... ... December 06, 2016 , ... Clinical Supplies ... has acquired the assets of Theorem Clinical Research - Clinical Supplies ("TCS"). ... trial drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials across ...
(Date:12/6/2016)... 6, 2016  The Texas Medical Center ... (HISA) today announced the establishment of a new ... Australia and the Texas Medical ... HISA and the Texas Medical Center, with ... create a global health innovation ecosystem where emerging technologies ...
(Date:12/5/2016)... Research and Markets has announced the addition of ... to their offering. ... , This report describes ... such as proteomics and metabolomics. Molecular diagnostics technologies are used for ... biomarker. Currently the most important applications of biomarkers are ...
Breaking Biology Technology:
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today introduced ... and their trainers non-invasively measure hemoglobin, Oxygen ... Rate, and Respiration Rate in approximately 30 seconds. Smaller ... easy and immediate access to key data about their ... a training regimen. Hemoglobin carries oxygen ...
(Date:11/22/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the company ... Life Sciences Awards as "Most Outstanding in eClinical ... year of recognition and growth for MedNet, which has ... iMedNet ™ , MedNet,s flagship ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, a ... for public safety, investigation, corrections and monitoring, announced today ... competitor, ICSolutions, to have an independent technology judge determine ... most modern high tech/sophisticated telephone calling platform, and the ... that they do most of what we do – ...
Breaking Biology News(10 mins):